Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
CN¥18.49 - CN¥27.26
Next Earnings Date
May 20 2025
Next Earnings Date
May 20 2025
Last Price
Market Cap | CN¥13.12B |
EV | CN¥12.67B |
Shares Outstanding | 563.16M |
Beta | 0.29 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | CN¥23.20 |
P/E 2025E | 16.48x |
P/Revenue 2025E | 3.26x |
Revenue | 9.10% |
EPS | 26.20% |
Operating Cash Flow | 1.20% |
Free Cash Flow | 4.00% |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 73.50% |
Net Profit Margin 2025E | 19.50% |
ROE 2025E | 24.40% |
ROCE 2024 | 24.65% |
DPS 2025E | CN¥1.00 |
Payout Ratio 2025E | 71.94% |
Div. Yield 2025E | 4.39% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Henan Lingrui Pharmaceutical Co., Ltd.
600285
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Xiong, Wei
Employees
2,530
Website
www.lingrui.comIPO Date
2000-10-18
Headquarters
No.666 Jiangjun Road, Xin County, Xinyang, Henan Province, 465550, China
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved